Integrated analysis of exosomal IncRNA and mRNA expression profiles reveals the involvement of Inc-MKRN2-42:1 in the pathogenesis of Parkinson’s disease

Qiao Wang¹,² | Chun-Lei Han¹,² | Kai-Liang Wang¹,² | Yun-Peng Sui¹,² | Zhi-Bao Li¹,² | Ning Chen³ | Shi-Ying Fan¹,² | Michitomo Shimabukuro¹,² | Feng Wang⁴ | Fan-Gang Meng¹,²,³

¹Department of Functional Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China
²Beijing Key Laboratory of Neurostimulation, Beijing, China
³Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
⁴Department of Neurosurgery, General Hospital of Ningxia Medical University, Yinchuan, China

Correspondence
Fan-Gang Meng, Beijing Neurosurgical Institute, Capital Medical University, No. 119, The South Fourth Ring Road, West Road, Fengtai District, Beijing 100070, China.
Email: mengfg@ccmu.edu.cn

Feng Wang, Department of Neurosurgery, General Hospital of Ningxia Medical University, 804 Shengli Street, Yinchuan, Ningxia 750001, China.
Email: nxwwang@163.com

Funding information
This work was supported by special funding support from the Beijing Municipal Administration of Hospitals Clinical Medicine Development program (grant XMLX201833), the Beijing Natural Science Foundation Program and Scientific Research Key Program of the Beijing Municipal Commission of Education (grant KZ201910025036), the National Natural Science Foundation of China (grant 81970170, 81701251 and 81660226), and the Key Research and Development Program of Ningxia (grant 2018BFG02007).

Abstract

Background: Parkinson’s disease (PD) is a common movement disorder for which diagnosis mainly depends on the medical history and clinical symptoms. Exosomes are now considered an additional mechanism for intercellular communication, allowing cells to exchange proteins, lipids, and genetic material. Long noncoding (Inc) RNA in exosomes plays a critical role in many diseases, including neurodegenerative disease.

Aim: To study expression differences for IncRNAs in peripheral blood exosomes of PD patients compared with healthy individuals and to look for IncRNAs that might be related to the pathogenesis of PD.

Materials and Methods: We recruited PD patients along with age- and sex-matched healthy individuals as healthy controls and evaluated levels of IncRNAs extracted from exosomes in plasma samples via next-generation sequencing and real-time quantitative PCR. Correlation analysis was conducted for the clinical characteristics of PD patients and the expression of selected IncRNAs.

Results: We found 15 upregulated and 24 downregulated exosomal IncRNAs in the PD group. According to bioinformatics analyses, we chose Inc-MKRN2-42:1 for further study. Interestingly, Inc-MKRN2-42:1 was positively correlated with the MDS-UPDRS III score for PD patients.

Conclusion: Our study suggested that Inc-MKRN2-42:1 may be involved in the occurrence and development of PD.

Keywords

exosome, Lnc-MKRN2-42:1, MDS-UPDRS III, next-generation sequencing, Parkinson’s disease
INTRODUCTION

Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease, with median age-standardized annual incidence rates in high-income countries of 14 per 100,000 individuals in the total population, and 160 per 100,000 among those aged 65 years or older. The clinical features of PD include resting tremor, rigidity, bradykinesia, and gesture failure, with a higher risk of nonmotor symptoms, including cognitive impairment and dementia. The main pathological changes in PD are the degeneration and death of dopaminergic neurons in the midbrain substantia nigra and significant decreases in dopamine in the striatum, resulting in an imbalance between dopamine and acetylcholine transmitters. The presence of Lewy bodies in substantia nigra cells is considered a pathological marker of PD. However, the exact mechanism underlying the PD remains unclear. Diagnosis of PD mainly depends on the medical history and clinical symptoms, which are easy to misdiagnose.

Exosomes are cell-derived membranous structures that originate from the endosomal system. They are present in blood, semen, saliva, urine, amniotic fluid, cerebrospinal, bile, breast milk, and culture medium from cell cultures, and range in size from 30 to 100 nm. Exosomes are now considered an additional mechanism for intercellular communication. Exosomes contain proteins, RNA, and DNA of their cell of origin, and the lipid bilayer can protect these specific contents from enzymatic degradation. In 2016, Fraser et al demonstrated that levels of autophosphorylated Ser(P)-1292 LRRK2 are elevated in urinary exosomes in cases of idiopathic PD. They also found that cognitive impairment severity and difficulty in performing daily activities were correlated with levels of urinary exosome Ser(P)-1292 LRRK2. Studies have shown that exosomes are involved in the transmission and release of α-synuclein, which is closely related to PD pathogenesis and dysfunction, and is the main component of Lewy bodies. Given the difficulty in obtaining brain tissue and the properties of exosomes, it is appropriate to use exosomes rather than brain tissue to study PD.

Long noncoding RNAs (lncRNAs) are noncoding RNAs with a length greater than 200 nucleotides (nt) that can comprehensively regulate gene expression through a variety of different mechanisms at epigenetic, transcription, posttranscription, and translation levels. In 2014, Soreq et al used whole-transcriptome RNA sequencing to screen 13 differentially expressed lncRNAs in peripheral PD leukocytes, five of which contained the spliceosome component U1, which supported the idea that splicing modulations were involved in the disease. Lnc-fr91.3 was believed to be related to muscle rigidity in PD. In 2015, Carrieri et al demonstrated that antisense transcription regulated sense genes functioned at distinct regulatory levels in PD and could be used as a new therapeutic strategy. In 2016, Kraus et al analyzed the lncRNA expression profile of brain tissues from PD patients and normal subjects and found that significant differences in the expression of lncRNA-p21, MALAT1, SNHG1, NEAT1, and H19. Such differences appeared in the early stages of PD and accompanied its development. These studies suggested that lncRNAs play an important role in the pathogenesis of PD, but the expression of lncRNAs in peripheral blood exosomes of PD patients remains unknown. In this study, we screened lncRNAs in peripheral exosomes from PD patients in order to identify valuable lncRNAs for further study.

METHOD

2.1 Participants

Thirty-two PD patients (Dnr_01 to Dnr_07; age 63 ± 11 years) and seven healthy controls (Dnr_34 to Dnr_40; age 58 ± 9 years) were selected for next-generation sequencing (NGS) of exosome lncRNAs. There was no significant difference in age between the two groups, and each group consisted of four males and three females. Peripheral blood samples from individuals were collected in ethylene diamine tetraacetic acid (EDTA) tubes following a regular venipuncture procedure. After centrifugation at 3000 × g for 15 minutes at 4°C, the plasma was aspirated and stored at −80°C before use. The ultracentrifugation method was optimized according to the method previously described. After thawing at 37°C, plasma samples were centrifuged at 3,000 × g for 15 minutes to remove cell debris. The supernatant was then diluted using a sevenfold volume of phosphate-buffered saline (PBS), centrifuged at 13,000 × g for 30 minutes, and processed through a 0.22 μm filter to remove large particles. The supernatant was ultracentrifuged using a P50A72-986 rotor (CP100NX; Hitachi, Brea, CA, USA) at 100,000 × g at 4°C for 2 hours to pellet the exosomes. The pellet was resuspended in PBS and centrifuged again at 100,000 × g at 4°C for 2 hours. After PBS washing, the exosome pellet was resuspended in 100 μL of PBS.

2.2 Exosome collection

Exosomes were identified via TEM, NTA, and Western blotting. A 20-μL aliquot of exosome solution was placed on a copper mesh
| Case | Diagnosis | Sex  | Age (y) | Course (y) | MDS-UPDRS3 | MoCA | HAMA | HAMD |
|------|-----------|------|---------|------------|-------------|------|------|------|
| Dnr_01 | PD        | Male | 52      | 6          | 52          | 9    | 28   | 30   |
| Dnr_02 | PD        | Male | 53      | 7          | 56          |      |      |      |
| Dnr_03 | PD        | Male | 72      | 8          | 67          |      |      |      |
| Dnr_04 | PD        | Female | 70     | 10         | 53          | 24   | 10   | 10   |
| Dnr_05 | PD        | Female | 54     | 16         | 71          | 18   | 45   | 44   |
| Dnr_06 | PD        | Male | 55      | 6          | 53          | 20   | 6    | 12   |
| Dnr_07 | PD        | Female | 74     | 5          | 52          | 17   | 29   | 30   |
| Dnr_08 | PD        | Female | 64     | 6          | 56          | 26   | 6    | 12   |
| Dnr_09 | PD        | Male | 76      | 21         | 88.6        | 16   | 31   | 17   |
| Dnr_10 | PD        | Male | 76      | 14         | 81          | 26   | 20   | 18   |
| Dnr_11 | PD        | Male | 66      | 12         | 73.1        | 26   | 14   | 5    |
| Dnr_12 | PD        | Male | 74      | 4          | 52.6        | 18   | 26   | 20   |
| Dnr_13 | PD        | Male | 64      | 8          | 69.4        | 22   | 12   | 13   |
| Dnr_14 | PD        | Male | 57      | 10         | 83          | 22   | 17   | 9    |
| Dnr_15 | PD        | Male | 68      | 9          | 73          | 26   | 21   | 16   |
| Dnr_16 | PD        | Female | 74     | 10         | 62          | 21   | 12   | 11   |
| Dnr_17 | PD        | Male | 63      | 5          | 46.7        | 20   | 22   | 30   |
| Dnr_18 | PD        | Female | 54     | 8          | 77.8        | 23   | 12   | 14   |
| Dnr_19 | PD        | Male | 66      | 10         | 61          | 24   | 10   | 2    |
| Dnr_20 | PD        | Male | 65      | 4          | 35.9        | 22   | 15   | 11   |
| Dnr_21 | PD        | Male | 59      | 8          | 63          | 24   | 15   | 6    |
| Dnr_22 | PD        | Female | 64    | 3          | 47          | 25   | 21   | 22   |
| Dnr_23 | PD        | Female | 50    | 5          | 52          | 18   | 17   | 10   |
| Dnr_24 | PD        | Male | 50      | 7          | 77          | 24   | 13   | 10   |
| Dnr_25 | PD        | Female | 66    | 14         | 18          | 14   | 14   | 8    |
| Dnr_26 | PD        | Male | 43      | 8          | 48          | 24   | 32   | 21   |
| Dnr_27 | PD        | Female | 54    | 10         | 37          | 22   | 11   | 21   |
| Dnr_28 | PD        | Female | 69    | 10         | 75          | 26   | 36   | 26   |
| Dnr_29 | PD        | Female | 38    | 10         | 63          | 22   | 15   | 16   |
| Dnr_30 | PD        | Male | 60      | 6          | 54          | 17   | 15   | 14   |
| Dnr_31 | PD        | Male | 64      | 14         | 34          | 15   | 17   | 13   |
| Dnr_32 | PD        | Female | 68    | 9          | 61          |      |      |      |
| Dnr_33 | HC        | Male | 25      |            |            |      |      |      |
| Dnr_34 | HC        | Male | 53      |            |            |      |      |      |
| Dnr_35 | HC        | Male | 51      |            |            |      |      |      |
| Dnr_36 | HC        | Male | 49      |            |            |      |      |      |
| Dnr_37 | HC        | Male | 60      |            |            |      |      |      |
| Dnr_38 | HC        | Female | 62     |            |            |      |      |      |
| Dnr_39 | HC        | Female | 56    |            |            |      |      |      |
| Dnr_40 | HC        | Female | 57    |            |            |      |      |      |
| Dnr_41 | HC        | Female | 52    |            |            |      |      |      |
| Dnr_42 | HC        | Female | 49    |            |            |      |      |      |
| Dnr_43 | HC        | Male | 45      |            |            |      |      |      |
| Dnr_44 | HC        | Male | 60      |            |            |      |      |      |
| Dnr_45 | HC        | Male | 67      |            |            |      |      |      |

Abbreviations: HAMA, Hamilton Anxiety Scale; HAMD, Hamilton Depression Scale; HC, healthy control; MDS-UPDRS, Movement Disorder Society-Sponsored Revision Unified Parkinson's Disease Rating Scale; MoCA, Montreal Cognitive Assessment; PD, Parkinson's disease.
and incubated at room temperature for 10 minutes. After washing with sterile distilled water, the exosomes were contrasted with uranyl oxalate solution for 1 minute. The sample was then dried for 2 minutes under incandescent light. The copper mesh was observed and photographed using a transmission electron microscope (JEOL-JEM1400, Tokyo, Japan). Vesicle suspensions with concentrations between $1 \times 10^7$/mL and $1 \times 10^8$/mL were examined using a ZetaView PXM 110 instrument (Particle Metrix, Meerbusch, Germany) equipped with a 405-nm laser to determine the size and quantity of particles isolated. A video of 60-s duration was recorded at a frame rate of 30 frames/s, and particle movement was analyzed using NTA software (ZetaView 8.02.28). The exosome supernatants were denatured in 5 × sodium dodecyl sulfate (SDS) buffer and subjected to Western blot analysis (10% SDS-polyacrylamide gel electrophoresis; 50 µg protein/lane) using rabbit polyclonal antibody CD63 (sc-5275; Santa Cruz Biotechnology, Santa Cruz, CA, USA), TSG101 (sc-13611; Santa Cruz Biotechnology), and calnexin (10427-2-AP; Promega, Madison, WI, USA). The antibody dilutions used for Western blots were 1:200 for TSG101 and CD63, and 1:1000 for Calnexin. The proteins were visualized on a Tanon 4600 automatic chemiluminescence image analysis system (Tanon, Shanghai, China).

2.4 ExoRNA isolation and RNA analyses

Total RNA was extracted and purified from plasma exosomes using a miRNeasy® Mini kit (Qiagen, Redwood City, CA, USA; cat. #217004) according to the kit instructions. RNA degradation and contamination, especially DNA contamination, were monitored on 1.5% agarose gels. The RNA concentration and purity were evaluated using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). RNA integrity was assessed using an RNA Nano 6000 assay kit on an Agilent Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA, USA).

A total of 5 ng of RNA per sample was used as input material for rRNA removal using a Ribo-Zero™ Magnetic kit (Epicentre, Madison, WI, USA). Sequencing libraries were generated using an Ovation RNA-Seq system (NuGEN, Redwood City, CA, USA) following the manufacturer’s recommendations, and index codes were added to attribute sequences to each sample. For small RNA libraries, a total amount of 2.5 µg of RNA per sample was used as input material for the RNA sample preparation. Sequencing libraries were generated using an NEB Next Multiplex Small RNA Library Prep Set for an Illumina kit (New England Biolabs, Ipswich, MA, USA) following the manufacturer’s recommendations. Index codes were added to attribute sequences to each sample. Finally, the PCR products were purified (AMPure XP system; Beckman Coulter, Brea, CA, USA) and library quality was assessed on an Agilent Bioanalyzer 2100 and by qPCR. Clustering of the index-coded samples was performed on an acBot cluster generation system using TruSeq PE Cluster KitV3-cBot-HS (Illumina, Foster City, CA, USA) according to the manufacturer’s instructions. After cluster generation, the library preparations were sequenced on an Illumina Hiseq platform and paired-end reads were generated. The transcriptome was assembled using the Cufflinks and Scripture programs based on reads mapped to the reference genome. The assembled transcripts were annotated using the Cuffcompare program from the Cufflinks package. Unknown transcripts were used to screen for putative lncRNAs. Three computational approaches (CPC, CNCI and Pfam) were combined to sort nonprotein-coding RNA candidates from putative protein-coding RNAs among the unknown transcripts. Putative protein-coding RNAs were filtered out using a minimum length and exon number threshold. Transcripts longer than 200 nt and having more than two exons were selected as IncRNA candidates and further screened using CPC/CNCI/Pfam, which has the power to distinguish protein-coding from noncoding genes. In addition to the different types of lncRNAs, lincRNA, intronic lncRNA, and antisense IncRNAs were selected using Cuffcompare (Figure S6).

Cuffdiff (v2.1.1) was used to calculate the fragments per kilobase of exon per million reads (FPKM) for both IncRNAs and coding genes in each sample. Gene FPKMs were computed by summing the FPKMs for transcripts in each gene group. FPKM was calculated based on the length of a fragment and read counts mapped to this fragment. Differential expression analysis of two conditions/groups was performed using the Mann-Whitney U test with significance cutoffs of $P \leq .05$ and $|\log2(\text{fold-change})| \geq 1.5$.

2.5 GO and KEGG pathway enrichment analysis

We predicted the target genes for the differentially expressed IncRNAs. Perl script was used to identify adjacent genes in the range of 100kb upstream and downstream of IncRNAs as cis target genes of IncRNAs. LncTar was used to predict the trans target genes of our IncRNAs. Gene Ontology (GO) enrichment analysis of the target genes for differentially expressed IncRNAs was carried out using the GOseq R packages based on a Wallenius noncentral hyper-geometric distribution. Kyoto Encyclopedia of Genes and Genomes (KEGG) is a database resource for understanding high-level functions and utilities of biological system (such as cell, organism, and ecosystem) from molecular-level information, especially large-scale molecular datasets generated via genome sequencing and other high-throughput experimental technologies (http://www.genome.jp/kegg/). We used KOBAS to test the statistical enrichment of differentially expressed genes in KEGG pathways.

2.6 Quantitative polymerase chain reaction (qPCR)

Total RNA was extracted from plasma samples from 24 PD patients (Dnr_8 to Dnr_31) and 11 healthy controls (Dnr_35 to Dnr_45) using an exoRNeasy Serum/Plasma Maxi Kit (Qiagen, Redwood City, CA, USA; cat. #77064). The DNA in the RNA residue was digested using a DNase I kit (CW Bio, Cambridge, MA, USA; cat. #CW2090).
The RNA was reverse transcribed into complementary DNA (cDNA) using a HiFi-MMLVcDNA kit (CW Bio; cat #CW0744) according to the manufacturer’s instructions. PCR was performed on the cDNA using UltraSYBR Mixture (With ROX; CW Bio; cat #CW0956). No electrophoresis was performed because of a low RNA yield. β-actin was used as a housekeeping gene. Data were calculated as relative expressions according to the \( \Delta\Delta C(t) \) principle.18,19 The primer sequences were 5′-GCA AGC CTA ACT CAA GCC ATT-3′ and 5′-TCA AGC CGA CTC TCC ATA CC-3′ for GAS5:46; and 5′-AGG TGG GAG GAT CGC TTG A-3′ and 5′-ACC ATA TTG ATG CCG AAC TTA GTG-3′ for lnc-MKRN2-42:1.

### 2.7 Statistical analysis

Data were analyzed using SPSS version 19.0 statistical software and GraphPad Prism 7.0. Data in all figures are expressed as mean ± standard error of the mean (s.e.m.). Data were compared using Student’s t-test (two groups). The Spearman’s rank test was used for statistical analysis of the gene expression data set and clinical characteristics. \( P < .05 \) was considered statistically significant.

### 3 RESULTS

#### 3.1 Clinical characteristics and exosome characterization and properties

Clinical characteristics were collected from medical records (Table 1). Movement Disorder Society-Sponsored Revision Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) III, Montreal Cognitive Assessment (MoCA), Hamilton Depression Scale (HAMD), and Hamilton Anxiety Scale (HAMA) scores were all evaluated by two physicians specializing in movement disorders. We used ultracentrifugation to isolate exosomes from human peripheral blood for NGS. Exosomes were verified using transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blots. TEM images showed exosomes as small cap-shaped membrane vesicles after fixation, adhesion, negative staining, and visualization (Figure 1A), consistent with previous observations.5 NTA is a method for direct, real-time visualization and analysis of nanoparticles in liquids and relates the rate of Brownian motion to particle size.20 The mean diameter of exosomes observed via NTA was consistent with the TEM results, confirming that the exosomes were small extracellular vesicles.21 CD63 and TSG101 were used as exosome surface protein markers, while calnexin was used as a negative marker,22 and their presence and absence were verified by our Western blot results (Figure 1B).

![Figure 1](image_url)

**FIGURE 1** Identification of exosomes. A, Transmission electron microscopy. B, Western blotting. Arrow indicates an exosome in (A). Cell lysis solution is the positive control of the WB experiment.

#### 3.2 Differential expression of IncRNAs and mRNAs between PD and healthy control individuals

All IncRNAs obtained from exosomal IncRNAs from PD patients and healthy control subjects were deep sequenced via NGS. The Q30 quality score for each sample was ≥91.54%. FPKM distributions for each sample are shown in (Figure S1). Total clean reads ranged from 124 679 284 to 194 592 044, with an average of 147 178 671. In total, 11.70% to 48.21% sequence reads aligned to the human genome sequence GRCh38. We used |log2(fold-change)| ≥ 1.5 and \( P \leq .05 \) as the thresholds for significantly differential expression. The results revealed 160 upregulated and 377 downregulated mRNAs, 70 upregulated and 41 downregulated miRNAs, 15 upregulated and 24 downregulated IncRNAs, and 62 upregulated and 37 downregulated circRNAs. The most differentially expressed IncRNAs are listed in Table S1. The location of genes on chromosomes is significantly related to their function. Therefore, we analyzed the distribution of differentially expressed IncRNA and mRNA sequences on chromosomes (Figure S2). According to the IncRNA differential expression results, MSTRG.336210.1 and lnc-MKRN2-42:1 were highly expressed among healthy subjects, while MSTRG.242001.1 and MSTRG.169261.1 were highly expressed among PD patients. The heatmap in Figure 2A, B provides a visual representation of
the differences in mRNA and lncRNA expression levels between the healthy and PD groups. The most differentially expressed transcriptomes are listed in Table S2. ACRBP, CXCL5, ENKUR, and others were highly expressed among PD patients, whereas NME4, CD3D, and ECSCR were highly expressed among healthy subjects.

3.3 | Functional annotation and enrichment analysis

We performed functional annotation of the target genes of differentially expressed lncRNAs. Nine cis target genes and seven trans target genes were functionally annotated. GO analysis showed that these genes are involved in “intracellular part,” “single-organism cellular process,” “heterocyclic compound binding,” etc (Figure 3). The pathways with the most significant enrichment are listed in Figure 3 (B, D). Remarkably, these target genes were enriched in “autophagy,” “fatty acid degradation,” “pentose phosphate pathway,” and “HIF-1 signaling pathway.”

To better understand the functions of the differentially expressed mRNAs described above, we performed GO and KEGG pathway enrichment analyses. GO annotations were obtained for approximately 499 differentially expressed mRNAs. GO analysis of these mRNA showed that they are involved in “immune system,” “biological phase,” and “cell killing” biological processes; are primarily enriched in “organelle part” and “macromolecular complex” cellular components; and are involved in molecular functions that include “translation regulator activity,” “structural molecular activity,” and “electron carrier activities” (Figure S3). In addition, KEGG annotation for 369 mRNAs were obtained (Figure S4). The pathways with the most significant enrichment are shown in Figure 3. Remarkably, these mRNAs were enriched in “the ribosome pathway,” “oxidative phosphorylation pathway,” “Parkinson’s disease pathway,” and “Huntington’s disease pathway” among others.

3.4 | Target gene prediction for lncRNA and qPCR validation

On the basis of the mode of action of lncRNAs and their target genes, we predicted the target genes for Inc-MKRN2-42:1 and GAS5:46.
The results for lncRNA and mRNA information analyses suggest that lnc-MKRN2-42:1 has a regulatory relationship with multiple target genes (Table 2). The target genes for lnc-MKRN2-42:1 are EIF4E, MKNK1, BTD, TMEM78, ZNF428, AC133555.3, ARHGAP8, METTL5, PACRG, GENPL, AC003002.2, ENSG00000279282, ENSG00000280175, etc. The target genes for GAS5:46 are CENPL, ZBTB37, SERPINC1, etc.

The downregulation trends for lnc-MKRN2-42:1 and GAS5:46 observed via qPCR are consistent with the NGS results. Compared with the healthy control group, BTD expression was approximately 71\% lower and EIF4E expression was approximately 25\% lower in the PD group, and the expression levels were positively correlated with lnc-MKRN2-42:1 (Figure 4). Therefore, we selected lnc-MKRN2-42:1 and its target genes for further correlation analysis.

### 3.5 Correlation analysis of differential expression and clinical characteristics

Correlation analysis was conducted between the clinical characteristics of PD patients and lnc-MKRN2-42:1 and GAS5:46 expression. The results demonstrate that lnc-MKRN2-42:1 expression was not correlated with HAMA, HAMD, and MoCA scores in PD (Figure S5). However, lnc-MKRN2-42:1 expression was positively correlated with MDS-UPDRS III score among PD...
patients. GAS5:46 was not correlated with any of the scales (Figure 5).

4 | DISCUSSION

This study included 32 PD patients and 13 healthy controls. We quantitatively analyzed IncRNA expression in peripheral blood vesicles from PD patients and healthy controls using NGS and real-time quantitative PCR. We identified 15 upregulated and 24 downregulated IncRNAs, of which Inc-MKRN2-42:1 was selected for further study. Bioinformatics analyses showed that Inc-MKRN2-42:1 could trans-regulate target genes such as BTD, EIF4E, MKNK1, and METTL5, involved in biological functions including apoptosis, synaptic remodeling, long-term potential, immunity, and glutamate neurotransmitter metabolism. Clinical correlation analyses showed that Inc-MKRN2-42:1 was positively correlated with MDS-UPDRS III scores for PD patients, suggesting that this IncRNA may be involved in the occurrence and development of PD. The process used to select Inc-MKRN2-42:1 is shown in Figure 6.

To ensure the experimental quality as far as possible, diseases that may cause changes in IncRNA expression levels were strictly excluded, and age and sex ratios were strictly defined in the selection of subjects for sequencing.

Compared with direct detection in peripheral blood, genetic materials in peripheral blood exosomes are more stable and can reflect pathological changes in the central nervous system (CNS). The study of exosomes in disease could provide important clues to the progression of neurodegenerative diseases and cancer. Previous studies provided evidence that amyloids involved in Alzheimer’s disease, such as amyloid β, are released via exosomes and that exosome-associated amyloids can act as seeds for plaque formation. Release of brain tumor vesicles and uptake by normal cells are associated with progression, angiogenesis, tumor cell invasion, and suppression of immune responses to the tumor. MiR-21 levels are higher in exosomes from the cerebrospinal fluid of glioblastoma patients when compared to healthy controls, while higher levels of MiR-21 are associated with poor prognosis and tumor recurrence. Previous studies also showed that exosomes released by prion-infected neuronal cells had higher let-7b, let-7i, miR-128a, miR-21, miR-29b, miR-342-3p, and miR-424 levels and lower miR-146a levels when compared to noninfected exosomes.

In the context of immune-mediated neuroinflammatory diseases, exosomes isolated from interferon-γ–stimulated dendritic cells, which are potent antigen-presenting immune cells, were enriched in miRNAs previously associated with anti-inflammatory processes, including miR-219. Brain extracts from a repetitive controlled cortical impact mouse model induced an

### TABLE 2 Target genes of Inc-MKRN2-42:1

| Target genes | Target type |
|--------------|-------------|
| BTD          | cis         |
| AL354828.2   | trans       |
| RP11-345J4.3 | trans       |
| ZNF428       | trans       |
| MKNK1        | trans       |
| TMEM78       | trans       |
| AC004076.7   | trans       |
| ARHGAP8      | trans       |
| EIF4E        | trans       |
| RP11-347C12.3| trans       |
| CENPL        | trans       |
| METTL5       | trans       |
| AL354828.1   | trans       |
| PACRG        | trans       |

**Figure 4** Expression (A, B) and correlation (C, D) of target genes. PD, Parkinson’s disease. (A, B) The expression levels of BTD and EIF4E in PD patients as determined using qPCR (n = 11-24). (A) C, D, Correlations according to spearman coefficient between the related expression level of target gene and the IncRNAs in PD patients. (n = 24)
increase in miR-124 in cultured BV2 microglia and their associated exosomes.\textsuperscript{26} Shi et al discovered that CNS-derived exosomes can efflux into blood and that the level of $\alpha$-synuclein from CNS-derived exosomes in plasma is substantially higher in PD patients and is associated with PD severity.\textsuperscript{27} Another study showed that exosomal miR-331-5p and miR-505 have diagnostic value for PD.\textsuperscript{28}

Recent studies have shown that lncRNAs are closely related to the pathogenesis of PD. High-throughput gene chip and sequencing screening results showed that a large number of lncRNAs are differentially expressed in brain tissues\textsuperscript{13,29} and peripheral blood\textsuperscript{11} of PD patients, PD animals,\textsuperscript{30} and cell models\textsuperscript{31,32} of PD, suggesting that lncRNAs are involved in the occurrence of PD. Abnormal expression of lncRNAs was observed in the early stages of PD.\textsuperscript{33,34} Preliminary functional studies confirmed that lncRNAs are involved in the occurrence and development of PD. Studies have shown that lncRNA, MAPT-AS1, with low expression in PD patients, can increase methylation of the MAPT promoter region and further increase expression of the MAPT gene.\textsuperscript{31} The lncRNA MALAT1 increased the protein stability of $\alpha$-synuclein in SH-SY5Y cells induced by MPP+.\textsuperscript{32} NEAT1, which is highly expressed in PD animals and cell models, can inhibit the degradation of PINK1 protein, and artificially disturbed NEAT1 can inhibit autophagy, improving damage to dopaminergic neurons.\textsuperscript{35} These studies suggest that lncRNAs play important roles in the pathogenesis of PD at an epigenetics level. However, the studies to date have not been systematic or in depth are mostly confined to in vitro analyses, and we know little about the roles of lncRNAs in exosomes in the pathogenesis of sporadic PD.

Lnc-MKRN2-42:1 is a newly discovered intergenic antisense lncRNA, located on human chromosome 3. It has a total length of 294 nt and contains only one exon. Currently, there are no reports on Lnc-MKRN2-42:1. As reported previously, EIF4E is involved in nuclear-transcribed mRNA catabolic processes, deadenylation-dependent

\begin{figure}
\centering
\includegraphics[width=\textwidth]{fig5}
\caption{Results of qPCR (A, B) and correlation analysis of lncRNA expression level and clinical characteristics (C, D). PD, Parkinson’s disease. MDS-UPDRS, Movement Disorder Society-Sponsored Revision Unified Parkinson’s Disease Rating. A, B, The expression levels of Lnc-MKRN2-42:1 and GAS5:46 in PD patients as determined using qPCR (n = 11-24). C, D, Correlations according to spearman coefficient between the related expression level of lncRNAs and the MDS-UPDRS III in PD patients. (n = 24)}
\end{figure}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{fig6}
\caption{Flowchart of the Lnc-MKRN2-42:1 selection process}
\end{figure}
The clinical manifestations of PD are complex. In addition to the typical movement disorder, balance impairments, restless leg syndrome, depression, anxiety, cognitive disorder, autonomic dysfunction, REM sleep behavior disorder, and speech disorder can occur. Therefore, we used the MDS-UPDRS, H&Y stage, and Berg Balance Scale to evaluate dyskinesia, HAMA to detect anxiety, HAMD to detect depression, and MMSE and MoCA to detect cognitive impairment. We analyzed the correlation between the results for most scales and lncRNA expression levels (Figure S5). Other scales were only used to determine the severity of a patient’s disease for more careful screening of the enrolled subjects. According to our results, Inc-MKRN2-42:1 expression levels were positively correlated with the severity of dyskinesia and dystrophy but were not correlated with other clinical symptoms, so only the correlation analysis for UPDRS III is presented here. Motor dysfunction, including tremor and rigidity, is the most noticeable symptom for PD patients and clinicians, and improvement in motor symptoms is the main index used to evaluate clinical efficacy. Therefore, Inc-MKRN2-42:1 could be used as a more objective and stable indicator to judge the development of a patient’s condition after further validation in a larger sample.

The sample size in this study is insufficient, and validation in a larger sample is still needed. It must be noted that the plasma samples used in this study were only from clinically diagnosed PD patients and further studies will be necessary to evaluate lncRNA expression in the early stages of PD. Future research will need to include a larger sample. It must be noted that the plasma sample.

In conclusion, we discovered that peripheral blood exosomes contained PD-associated Inc-MKRN2-42:1, and its expression level was correlated with PD patients’ clinical scores. Further research will explore whether Inc-MKRN2-42:1 is suitable as a new biomarker for PD.

CONFLICTS OF INTEREST
The authors have no conflicts of interest to disclose.

ORCID
Fan-Gang Meng https://orcid.org/0000-0002-8577-6443
25. Bellingham SA, Coleman BM, Hill AF. Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. *Nucleic Acids Res*. 2012;40(21):10937-10949.

26. Huang S, Ge X, Yu J, et al. Increased miR-124-3p in microglial exosomes following traumatic brain injury inhibits neuronal inflammation and contributes to neurite outgrowth via their transfer into neurons. *FASEB J*. 2018;32(1):512-528.

27. Shi M, Liu C, Cook TJ, et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease. *Acta Neuropathol*. 2014;128(5):639-650.

28. Yi Y, Mw Q, Gc L, Fb Z, Hc R. Circulating exosomal miRNAs as diagnostic biomarkers in Parkinson's disease. *Eur Rev Med Pharmacol Sci*. 2018;22(16):5278-5283.

29. Ni Y, Huang H, Chen Y, Cao M, Zhou H, Zhang Y. Investigation of long non-coding rna expression profiles in the substantia nigra of Parkinson's disease. *Cell Mol Neurobiol*. 2016;37(2):329-338.

30. Jiao F, Wang Q, Zhang P, Bu L, Yan J, Tian B. Expression signatures of long non-coding RNA in the substantia nigra of pre-symptomatic mouse model of Parkinson's disease. *Behav Brain Res*. 2017;331:123-130.

31. Coupland KG, Kim WS, Halliday GM, Hallupp M, Dobson-Stone C, Kwok JB. Role of the long non-coding RNA MAPT-AS1 in regulation of microtubule associated protein tau (MAPT) expression in Parkinson's disease. *PLoS ONE*. 2016;11(6):e0157924.

32. Zhang Q-S, Wang Z-H, Zhang J-L, Duan Y-L, Li G-F, Zheng D-L. Beta-asarone protects against MPTP-induced Parkinson's disease via regulating long non-coding RNA MALAT1 and inhibiting α-synuclein protein expression. *Biomed Pharmacother*. 2016;83:153-159.

33. Lin D, Liang Y, Jing X, et al. Microarray analysis of an synthetic alpha-synuclein induced cellular model reveals the expression profile of long non-coding RNA in Parkinson’s disease. *Brain Res*. 2018;1678:384-396.

34. Wang L, Yang H, Wang Q, et al. Paraquat and MPTP induce alteration in the expression profile of long noncoding RNAs in the substantia nigra of mice: Role of the transcription factor Nrf2. *Toxicol Lett*. 2018;291:11-28.

35. Yan W, Chen ZY, Chen JQ, Chen HM. LncRNA NEAT1 promotes autophagy in MPTP-induced Parkinson’s disease through stabilizing PINK1 protein. *Biochem Biophys Res Commun*. 2018;496(4):1019-1024.

36. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. *Mol Cell Biol*. 2004;24(1):200-216.

37. Asakawa T, Fang H, Sugiyama K, et al. Human behavioral assessments in current research of Parkinson's disease. *Neurosci Biobehav Rev*. 2016;68:741-772.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Wang Q, Han C-L, Wang K-L, et al. Integrated analysis of exosomal lncRNA and mRNA expression profiles reveals the involvement of lnc-MKRN2-42:1 in the pathogenesis of Parkinson's disease. *CNS Neurosci Ther*. 2020;26:527–537. [https://doi.org/10.1111/cns.13277](https://doi.org/10.1111/cns.13277)